AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23140547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge
Number of subjects: 102
Study 23140547 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 102
Study 21667009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity rehabilitation programme
Number of subjects: 79
Study 21667009 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity rehabilitation programme
Number of subjects: 79
Study 19886513 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly folic acid (5,000 or 2,800 microg) plus iron, zinc, and vitamin B-12 for 12 weeks
Number of subjects: 459
Study 19886513 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily folic acid (400 or 200 microg) plus iron, zinc, and vitamin B-12 for 12 weeks
Number of subjects: 459
Study 19886513 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 459
Study 16702169 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling sessions (8 sessions over 3 months)
Number of subjects: 186
Study 16702169 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed materials sent to intervention group participants
Number of subjects: 186
Study 16702169 — intervention group
Group type: COMPARATOR
Intervention: Outcome assessments only (control group)
Number of subjects: 186
Study 15585987 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 75
Study 15585987 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 75
Study 15585987 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 75
Study 11590256 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rh-Epo)
Number of subjects: 0
Study 11590256 — intervention group
Group type: EXPERIMENTAL
Intervention: Early correction of anaemia
Number of subjects: 0
Study 11590256 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Hb levels
Number of subjects: 0
Study 9217033 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg per day
Number of subjects: 91
Study 9217033 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg per day
Number of subjects: 91
Study 7954485 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 30
Study 7954485 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 30
Study 3064085 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 93426 (benzodiazepine receptor antagonist with weak inverse agonist properties)
Number of subjects: 0
Study 3064085 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 93426
Number of subjects: 0
Study 3064085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29637820 — intervention group
Group type: EXPERIMENTAL
Intervention: hUCB‐MSC infusion (4 infusions at a fixed dose of 5 × 10^7) with basic rehabilitation
Number of subjects: 54
Study 29637820 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline with basic rehabilitation (Control group)
Number of subjects: 54
Study 29637820 — intervention group
Group type: EXPERIMENTAL
Intervention: hUCB‐MSC infusion
Number of subjects: 54
Study 29637820 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine MRI exams
Number of subjects: 54
Study 28675975 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH) and intraoperative cell salvage (ICS)
Number of subjects: 44
Study 28675975 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative cell salvage (ICS) only
Number of subjects: 44
Study 25641606 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day for 14 days coadministered with aspirin 150 mg/day for 6 days
Number of subjects: 0
Study 25641606 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day for 14 days with maintenance warfarin (1-10 mg)
Number of subjects: 0
Study 25641606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23052718 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration panretinal photocoagulation (PRP) (20 milliseconds)
Number of subjects: 33
Study 23052718 — intervention group
Group type: COMPARATOR
Intervention: Conventional panretinal photocoagulation (PRP) (100 milliseconds)
Number of subjects: 33
Study 23052718 — intervention group
Group type: COMPARATOR
Intervention: Conventional PRP
Number of subjects: 33
Study 23052718 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration PRP
Number of subjects: 33
Study 21959614 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 106
Study 21959614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 18416081 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus shenqi fuzheng injection
Number of subjects: 126
Study 18416081 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 126
Study 21948041 — intervention group
Group type: EXPERIMENTAL
Intervention: IMB model-based intervention
Number of subjects: 152
Study 21948041 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 152
Study 16858933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime calcium supplementation (2 calcium carbonate tablets, 334 mg per tablet)
Number of subjects: 36
Study 16858933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime calcium supplementation
Number of subjects: 36
Study 16858933 — intervention group
Group type: COMPARATOR
Intervention: Post meal calcium supplementation
Number of subjects: 36
Study 12032788 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg loading dose of aminophylline
Number of subjects: 61
Study 12032788 — intervention group
Group type: COMPARATOR
Intervention: 6 mg/kg loading dose of aminophylline
Number of subjects: 61
Study 10212871 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous gastrostomy tube placement
Number of subjects: 105
Study 8529534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nalmefene glucuronide
Number of subjects: 5
Study 8529534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 2227078 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac tromethamine
Number of subjects: 129
Study 2227078 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac tromethamine
Number of subjects: 129
Study 2227078 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pethidine
Number of subjects: 129
Study 2227078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 150487 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (continuous administration for 16 weeks)
Number of subjects: 0
Study 150487 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study 12207836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg twice/d) and Vitamin E (100 mg twice/d) for 12 weeks
Number of subjects: 100
Study 12207836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12207836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and Vitamin E supplementation
Number of subjects: 100
Study 31502637 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 114
Study 31502637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 29571976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 40
Study 29571976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 40
Study 29571976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C plus Vitamin E
Number of subjects: 40
Study 29571976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26790705 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (10 µg/kg for five days)
Number of subjects: 114
Study 26790705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 24886264 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone peer support (two calls within the first ten days postpartum, then weekly calls until week twelve, with continued contact until six months postpartum)
Number of subjects: 0
Study 24886264 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 22325807 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive staff-patient relationships
Number of subjects: 204
Study 22325807 — intervention group
Group type: COMPARATOR
Intervention: Neutral staff-patient relationships
Number of subjects: 204
Study 22325807 — intervention group
Group type: EXPERIMENTAL
Intervention: Care co-ordinators with positive relationships
Number of subjects: 204
Study 20973465 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (Sprinkles) - 60 sachets (12.5 mg elemental iron) taken daily for 2 months
Number of subjects: 2193
Study 20973465 — intervention group
Group type: COMPARATOR
Intervention: Control group (no micronutrient powder)
Number of subjects: 2193
Study 17509150 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT-HaNSA
Number of subjects: 41
Study 17509150 — intervention group
Group type: COMPARATOR
Intervention: DASH
Number of subjects: 41
Study 17509150 — intervention group
Group type: COMPARATOR
Intervention: SPADI
Number of subjects: 41
Study 16176737 — intervention group
Group type: EXPERIMENTAL
Intervention: Continence nurse practitioner intervention (8-week primary intervention package including advice on diet and fluids; bladder training; pelvic floor awareness and lifestyle advice)
Number of subjects: 3746
Study 16176737 — intervention group
Group type: EXPERIMENTAL
Intervention: Continence nurse practitioner intervention
Number of subjects: 3746
Study 16176737 — intervention group
Group type: COMPARATOR
Intervention: Standard care (existing primary care including GP and continence advisory services)
Number of subjects: 3746
Study 16176737 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3746
Study 12534637 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (mean rate 9.2 +/- 2.6 micro g kg‐1 min‐1)
Number of subjects: 75
Study 10390684 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised information leaflet
Number of subjects: 235
Study 10390684 — intervention group
Group type: COMPARATOR
Intervention: Original information leaflet
Number of subjects: 235
Study 8888381 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 18
Study 8888381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1894824 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadup activity
Number of subjects: 64
Study 1894824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leadup activity)
Number of subjects: 64
Study 6614417 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 0
Study 6614417 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 0
Study 31587722 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity mannequin simulation
Number of subjects: 0
Study 31587722 — intervention group
Group type: COMPARATOR
Intervention: Virtual simulation
Number of subjects: 0
Study 29560057 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby shampoo (n=21)
Number of subjects: 58
Study 29560057 — intervention group
Group type: COMPARATOR
Intervention: Water irrigation (control, n=19)
Number of subjects: 58
Study 29560057 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby shampoo (n=10)
Number of subjects: 58
Study 29560057 — intervention group
Group type: COMPARATOR
Intervention: Water irrigation (control, n=8)
Number of subjects: 58
Study 26748101 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based intervention (CO)
Number of subjects: 6251
Study 26748101 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person intervention (PE)
Number of subjects: 6251
Study 24894386 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.05 to 0.2 μg.kg⁻¹.min⁻¹ for 24 hours)
Number of subjects: 516
Study 24894386 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 hours
Number of subjects: 516
Study 21720841 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 60
Study 21720841 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 60
Study 21194606 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg test formulation of rifampicin
Number of subjects: 14
Study 21194606 — intervention group
Group type: COMPARATOR
Intervention: 150-mg reference formulation of rifampicin
Number of subjects: 14
Study 21194606 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg test formulation of 25-desacetyl rifampicin
Number of subjects: 14
Study 21194606 — intervention group
Group type: COMPARATOR
Intervention: 150-mg reference formulation of 25-desacetyl rifampicin
Number of subjects: 14
Study 21194606 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioequivalence assessment for rifampicin
Number of subjects: 14
Study 21194606 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioequivalence assessment for 25-desacetyl rifampicin
Number of subjects: 14
Study 17606479 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI
Number of subjects: 40
Study 17606479 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil TCI
Number of subjects: 40
Study 16260708 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 0
Study 11895467 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (0.1, 0.3, 1.0 and 3.0 microg min‐1 dL‐1)
Number of subjects: 27
Study 10197802 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin (AmBisome) 2 mg/kg three times weekly
Number of subjects: 161
Study 10197802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 7556234 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (200 mg/day)
Number of subjects: 34
Study 7556234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 2090473 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water
Number of subjects: 16
Study 2090473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 16
Study 2090473 — intervention group
Group type: COMPARATOR
Intervention: Methacholine challenge
Number of subjects: 16
Study 7420656 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer reminders
Number of subjects: 0
Study 7420656 — intervention group
Group type: COMPARATOR
Intervention: Computer reminders with relevant medical literature citations
Number of subjects: 0
Study 31146330 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-adjustable standing desks for 6 months
Number of subjects: 38
Study 31146330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no standing desks)
Number of subjects: 38
Study 27994066 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+TMZ
Number of subjects: 196
Study 27994066 — intervention group
Group type: COMPARATOR
Intervention: RT+NU
Number of subjects: 196
Study 27994066 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH1 positive patients
Number of subjects: 196
Study 27994066 — intervention group
Group type: COMPARATOR
Intervention: IDH1 negative patients
Number of subjects: 196
Study 26095068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk product containing probiotic (FMPP) 65 mL/day for 6 weeks
Number of subjects: 45
Study 26095068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 26095068 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label FMPP treatment
Number of subjects: 45
Study 26095068 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal phase after open-label FMPP treatment
Number of subjects: 45
Study 26095068 — intervention group
Group type: COMPARATOR
Intervention: Both FMPP and placebo
Number of subjects: 45
Study 24285428 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) 360 µg thrice weekly for 8 weeks
Number of subjects: 200
Study 24285428 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) 720 µg thrice weekly for 8 weeks
Number of subjects: 200
Study 24285428 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) 1080 µg thrice weekly for 8 weeks
Number of subjects: 200
Study 22211999 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA therapy for 12 months
Number of subjects: 30
Study 22211999 — intervention group
Group type: COMPARATOR
Intervention: Control biopsies from 5 healthy volunteers
Number of subjects: 30
Study 19384844 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal CAC (CACS 0 to 30)
Number of subjects: 36
Study 19384844 — intervention group
Group type: COMPARATOR
Intervention: High CAC (CACS > 30)
Number of subjects: 36
Study 19384844 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 36
Study 19384844 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients with CACS progression
Number of subjects: 36
Study 19384844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral metabolism control
Number of subjects: 36
Study 17445011 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI for STEMI
Number of subjects: 189
Study 16234063 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 0
Study 12518180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine-GITS
Number of subjects: 116
Study 12518180 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-ER
Number of subjects: 116
Study 12518180 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 116
Study 10417626 — intervention group
Group type: EXPERIMENTAL
Intervention: Base cream containing sonicated Streptococcus thermophilus
Number of subjects: 17
Study 10417626 — intervention group
Group type: EXPERIMENTAL
Intervention: Base cream containing purified bacterial neutral sphingomyelinase
Number of subjects: 17
Study 10417626 — intervention group
Group type: COMPARATOR
Intervention: Inhibition of bacterial neutral sphingomyelinase activity through glutathione
Number of subjects: 17
Study 8625149 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin (1 mg every 8 hours for 14 days)
Number of subjects: 25
Study 8625149 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 patients undergoing endoscopic and surgical biopsy)
Number of subjects: 25
Study 2285172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (handwashing educational program, use of vinyl gloves, use of disposable diaper changing pads, use of alcohol-based hand rinse)
Number of subjects: 24
Study 2285172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 7237203 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg
Number of subjects: 99
Study 7237203 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg
Number of subjects: 99
Study 7237203 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg
Number of subjects: 99
Study 7237203 — intervention group
Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 99
Study 7237203 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 99
Study 29792087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy (ISTDP)
Number of subjects: 32
Study 29792087 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 32
Study 31133219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) program
Number of subjects: 32
Study 29091570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 110
Study 29091570 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 110
Study 27802556 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Cranial Manipulative Medicine (OCMM)
Number of subjects: 89
Study 27802556 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (light pressure applied to the cranium)
Number of subjects: 89
Study 24853043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus NCFM alone for 21 days at a total dose of 2 × 10(10) CFU b.d.
Number of subjects: 20
Study 24853043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus NCFM in combination with B-LBi07 for 21 days at a total dose of 2 × 10(10) CFU b.d.
Number of subjects: 20
Study 24853043 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (L-NCFM alone and L-NCFM with B-LBi07)
Number of subjects: 20
Study 23265162 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-surface composites (MSC)
Number of subjects: 40
Study 23265162 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel crowns (SSC)
Number of subjects: 40
Study 18977159 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 174
Study 18977159 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 174
Study 18977159 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained-release hydromorphone
Number of subjects: 174
Study 17210048 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to Ara h 2 at low concentration (0.1 micro g/mL)
Number of subjects: 30
Study 17210048 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to Ara h 6 at low concentration (0.1 micro g/mL)
Number of subjects: 30
Study 17210048 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to Ara h 1 at high concentration (100 micro g/mL)
Number of subjects: 30
Study 17210048 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to Ara h 3 at high concentration (100 micro g/mL)
Number of subjects: 30
Study 17210048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative SPT response
Number of subjects: 30
Study 17210048 — intervention group
Group type: COMPARATOR
Intervention: Eliciting dose (ED)
Number of subjects: 30
Study 15097240 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (25 or 50 mg daily)
Number of subjects: 24
Study 15097240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24